Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy

Core Insights - Servier and Black Diamond Therapeutics have entered into a strategic worldwide licensing agreement for BDTX-4933, a targeted therapy for solid tumors, with Servier responsible for its development and commercialization [1][2][6] - The agreement includes an upfront payment of $70 million to Black Diamond, with potential additional payments of up to$710 million based on development and commercial milestones, along with tiered royalties on global net sales [2][6] Company Overview - Servier is a global pharmaceutical group governed by a non-profit foundation, focusing on significant unmet medical needs and investing approximately 70% of its R&D budget in oncology [5][6] - Black Diamond Therapeutics specializes in developing MasterKey therapies targeting oncogenic mutations, with a focus on precision medicine to address a broad spectrum of genetically defined tumors [8] Product Development - BDTX-4933 is currently in Phase 1 development, specifically designed to target RAS and RAF alterations in solid tumors, including non-small cell lung cancer (NSCLC) [3][6] - The ongoing clinical trial aims to evaluate the safety, tolerability, and preliminary antitumor activity of BDTX-4933 in adults with recurrent advanced/metastatic cancers harboring specific mutations [3][6]